Overview

The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes

Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in the daily life of participants with type 1 Diabetes
Phase:
N/A
Details
Lead Sponsor:
Steno Diabetes Center
Steno Diabetes Center Copenhagen
Treatments:
Gastric Inhibitory Polypeptide